Exogene

Exogene is an Oxford biotech developing TCR-based immunotherapies for solid tumours.

Its platform integrates generative AI, biophysical simulation, and high-throughput TCR-antigen screening to identify rare, high-affinity cancer-specific T-cell receptors from patient tumour samples.

The company develops TCR-T cell therapies in which patient-derived T cells are genetically reprogrammed with engineered TCRs and reintroduced to eliminate cancer cells, with a lead programme targeting non-small cell lung cancer.

Exogene has a research collaboration with Immunocore.